TICKERNERD
Menu
SPTXHealthcare · Biotechnology

SPTX Stock Forecast: Seaport Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$17
+3.73% on the day

The 9 Wall Street analysts covering Seaport Therapeutics, Inc. hold a median 12-month price target of $35 — +109.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 14 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$892.9M
Ticker Nerd rank
2 / 100
Median analyst target
$35
Analysts covering
9
Total return, dividends reinvested
1W
−7.0%
1M
−32.5%
From high
−40.1%
From low
+9.4%
$15
$28
Range since 1 May 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

SPTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Seaport Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
2 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
45
Revisions
39
Value
11
Issuance
11
Accruals
8
Growth
8
Quality
5
Momentum
4
Volatility
3

Size (45): Smaller than most of the companies we track.

Volatility (3): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SPTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SPTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 1 May 2026Adjusted close, US dollars
$10$20$30$40$50May 26Jun 26Jul 26Aug 26Sep 26Oct 26SPTXHigh $50Median $35Low $28

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
8 Buy1 Hold0 Sell
Low $28Median $35High $50

The green dot is the last close — the median target sits +109.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Oct 2026Canaccord GenuityInitiatesBuy$28
8 Oct 2026HC Wainwright & Co.ReiteratesBuy$50
25 Sept 2026Raymond JamesInitiatesStrong Buy—
25 Sept 2026Raymond JamesInitiatesStrong Buy$46
10 Sept 2026HC Wainwright & Co.ReiteratesBuy—
10 Sept 2026HC Wainwright & Co.ReiteratesBuy$50
26 Aug 2026Jones TradingInitiatesBuy—
26 Aug 2026Jones TradingInitiatesBuy$32
20 Aug 2026HC Wainwright & Co.ReiteratesBuy—
20 Aug 2026HC Wainwright & Co.ReiteratesBuy$50
4 Aug 2026HC Wainwright & Co.ReiteratesBuy$50
4 Aug 2026HC Wainwright & Co.ReiteratesBuy—
15 July 2026HC Wainwright & Co.InitiatesBuy$50
15 July 2026HC Wainwright & Co.InitiatesBuy—
26 May 2026CitigroupInitiatesBuy$35
26 May 2026CitigroupInitiatesBuy—
26 May 2026JP MorganInitiatesOverweight—
26 May 2026JP MorganInitiatesOverweight$42
26 May 2026Leerink PartnersInitiatesOutperform$35
26 May 2026Leerink PartnersInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SPTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SPTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

SPTX vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130140May 26Jun 26Jul 26Aug 26Sep 26Oct 26SPTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SPTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Seaport Therapeutics, Inc. (SPTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−8.6×

Cheaper than 93% of US stocks

Price / sales
—
Price / book
2.1×

Cheaper than 41% of US stocks

EV / EBITDA
−4.1×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
80.9%

Higher than 95% of US stocks

Return on assets
−30.1%

Higher than 14% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Seaport Therapeutics, Inc. (SPTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Seaport Therapeutics, Inc. has a market value of $892.9M and an enterprise value of $592.5M.

  • Shares outstanding: 53.0M.

  • Trailing P/E: −8.6×; forward P/E: −6.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Seaport Therapeutics, Inc. employs 58 people.

market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

SPTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SPTXSeaport Therapeutics, Inc.$892.9M
2
LTGOLatigo Biotherapeutics, Inc.$885.3M
1
MGTXMeiraGTx Holdings Plc$871.0M
82
SLBTSL Science Holding Ltd.$869.2M
0
RIGLRigel Pharmaceuticals, Inc.$866.3M
83
MLTXMoonLake Immunotherapeutics$863.0M
17
AKTSAktis Oncology, Inc.$911.5M
1

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Seaport Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SPTX news & analysis

PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

Business Wire · 9 Oct 2026positive

Seaport Therapeutics presented additional pharmacokinetic data from the Phase 1 clinical trial of GlyphAgo at the 39th ECNP Congress, according to Business Wire.

Why it matters — The presentation shares an update on Phase 1 GlyphAgo research relevant to SPTX watchers.

Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

Business Wire · 9 Oct 2026positive

Seaport Therapeutics announced that it presented additional pharmacokinetic data from the Phase 1 clinical trial of GlyphAgo (SPT-320) at the 39th ECNP Congress in Munich. The poster is the first scientific presentation of data from the GlyphAgo Phase 1 trial.

Why it matters — The presentation provides SPTX watchers with an update on clinical data for the company’s GlyphAgo program.

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance

Business Wire · 7 Oct 2026positive

Seaport Therapeutics announced that the first patient has been dosed in its Phase 2a clinical trial evaluating GlyphAgo in patients with generalized anxiety disorder and sleep disturbance.

Why it matters — The trial's first patient dosing marks a clinical development milestone for Seaport's GlyphAgo program.

Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance

Business Wire · 7 Oct 2026positive

Seaport Therapeutics announced that the first patient has been dosed in a Phase 2a clinical trial evaluating GlyphAgo in patients with generalized anxiety disorder and sleep disturbance.

Why it matters — The trial’s first patient dose marks a clinical-development milestone for SPTX’s GlyphAgo program in these patient populations.

Seaport Therapeutics to Participate in September Investor Conferences

Business Wire · 14 Sept 2026neutral

Seaport Therapeutics announced that members of its management team, including Co-Founder and CEO Daphne Zohar, will participate in additional investor conferences in September, featuring a company presentation and a panel discussion at the Goldman Sachs Life Sciences Sympo.

Why it matters — SPTX watchers would care because the company is increasing its investor visibility through management presentations and panel participation at a major industry conference.

FAQ

Frequently asked questions about SPTX stock

What is the SPTX stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Seaport Therapeutics, Inc. have a median 12-month price target of $35, with estimates ranging from $28 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SPTX stock a buy right now?

Of the 9 analysts covering Seaport Therapeutics, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Seaport Therapeutics, Inc. 2 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SPTX?

As at 14 Oct 2026, Seaport Therapeutics, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (45 of 100).

Will SPTX stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +109.8% from the last close, and Ticker Nerd's factor model ranks Seaport Therapeutics, Inc. 2 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SPTX stock forecast for 2030?

No analyst covering Seaport Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $28 to $50 over the next 12 months.

What does Seaport Therapeutics, Inc. do?

Seaport Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing medicines for depression, anxiety, and other debilitating neuropsychiatric disorders.

What is the latest news on SPTX?

The most recent item we track (Business Wire, 9 Oct 2026): "PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress". Seaport Therapeutics presented additional pharmacokinetic data from the Phase 1 clinical trial of GlyphAgo at the 39th ECNP Congress, according to Business Wire.

Company

About Seaport Therapeutics, Inc.

Seaport Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing medicines for depression, anxiety, and other debilitating neuropsychiatric disorders. The company’s current pipeline is built around its proprietary Glyph platform, which is designed to advance orally administered therapies based on clinically validated mechanisms while improving delivery characteristics and reducing limitations associated with existing treatments. Its lead programs include GlyphAllo, an oral prodrug of allopregnanolone being developed for postpartum depression, and GlyphAgo, an oral prodrug of agomelatine being developed for anxiety and depression. Seaport Therapeutics works at the intersection of neuropsychiatry and drug development, targeting conditions with significant unmet medical need through a portfolio of product candidates intended for future clinical and commercial use. Headquartered in Boston, Massachusetts, Seaport Therapeutics is positioned as a specialized biopharmaceutical company with a focused approach to central nervous system therapeutics.

CEO Ms. Daphne Zohar · 58 employees · United States · https://www.seaporttx.com